OR WAIT 15 SECS
A new defined coated cell cultureware by denovoMATRIX allow for the serum-free expansion of mesenchymal stem cells.
A new product introduced by denovoMATRIX, a German company that develops and manufactures biomimetic coatings for cultivating human stem cells, enhances the expansion process for human mesenchymal stem cells (hMSC). The new product, myMATRIX MSC, promotes adhesion, proliferation, and high viability of hMSC. The novel surface of the product supports long-term expansion of hMSCs over 10 passages and more than 25 population doublings. Furthermore, myMATRIX MSC enables expansion of hMSC in both serum-free and xeno-free media conditions.
Due to their high accessibility and extensive beneficial properties, hMSC offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment.
Currently, bovine-derived fetal calf serum and human plasma-derived fibronectin are commonly used in hMSC culture. These biological extracts frequently reduce experimental reproducibility, however, and represent a liability for hMSC manufacturers. To increase lot-to-lot consistency and eliminate the risk of transmission of xenogenic infectious agents, defined cell culture conditions, including media and extracellular matrix mimetic coatings, are essential, according to the company.
denovoMATRIX launched the new cultureware in August 2019.